Table 1.

Baseline profiles, response, and outcome of seven patients with HCC

Case	Age(yr)	Sex	PS	Hepatitis	Child-Pugh class	AFP (ng/mL)	L3 (%)	DCP (mAU/mL)	Main tumor size (mm)	Main tumor morphology	Vascular invasion	Tumor location	Tumor volume	Previous treatment	Treatment cycles	Response	Outcome (mo)	Cause of death
1	40	M	0	HBV	A	934.3	15.9	333	50	Massive	Vp3/Vv0	Bilobular, multiple	< 50%	None	2	PR	55, alive
2	35	M	0	HBV	A	593 350	1.9	> 2000	130	Massive	Vp4/Vv3	Bilobular, multiple	≥ 50%	HAI	3	PR	10, dead	Respiratory failure due to lung metastases
3	51	M	0	HBV	A	33 460	78	> 2000	80	Massive	Vp3/Vv0	Bilobular, multiple	< 50%	HAI	3	PR	8, dead	SAH due to a cerebral aneurysm
4	60	M	0	HCV	A	12.4	35.5	> 2000	45	Massive	Vp3/Vv0	Bilobular, multiple	≥ 50%	HAI	1	PR	6, dead	Intrahepatic HCC related liver failure
5	68	M	0	HCV	A	7.5	< 0.5	86	42	Nodular	Vp0/Vv0	Bilobular, multiple	< 50%	TACE	1	SD	25, dead	Aspiration-related pneumonia due to vertebra metastasis
6	64	M	0	HCV	A	127 920	64.3	698	45	Nodular	Vp3/Vv0	Bilobular, multiple	< 50%	TACE	2	SD	7, dead	Intrahepatic HCC related liver failure
7	42	M	0	HBV	A	372.8	67.5	15	100	Diffuse	Vp4/Vv0	Bilobular, multiple	≥ 50%	TACE	2	SD	5, dead	Intrahepatic HCC related liver failure

Vp0: No PVTT; Vp3: PVTT in the first branch; Vp4: PVTT in the trunk; Vv0: No hepatic venous tumor thrombus; Vv3: Hepatic venous tumor thrombus in inferior vena cava; Multiple lesions; massive type HCC; Nodular, nodular type HCC; diffuse type HCC; Bilobular: Lesions; HAI: Hepatic arterial infusion chemotherapy of low-dose cisplatin and 5-FU.